Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 462

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 462
---
/s/
WithumSmith+Brown, PC

We
have served as the Company’s auditor since 2021.

New
York, New York

March
31, 2025

PCAOB
ID Number 100

F-2

bioAffinity
Technologies, Inc.

Consolidated
Balance Sheets 

as of December 31, 2024 and 2023

    December
    31, 

    2024  
    2023 
  
    ASSETS 

    Current assets: 

    Cash and
    cash equivalents 
    $1,105,291  
    $2,821,570 
  
    Accounts and other receivables,
    net 
     1,139,204  
     811,674 
  
    Inventory 
     27,608  
     18,484 
  
    Prepaid
    expenses and other current assets 
     422,995  
     321,017 

    Total current assets 
     2,695,098  
     3,972,745 

    Non-current assets: 

    Property and equipment,
    net 
     375,385  
     458,633 
  
    Operating lease right-of-use
    asset, net 
     463,011  
     370,312 
  
    Finance lease right-of-use
    asset, net 
     780,872  
     1,165,844 
  
    Goodwill 
     1,404,486  
     1,404,486 
  
    Intangible assets, net 
     775,139  
     833,472 
  
    Other
    assets 
     19,676  
     16,060 

    Total assets 
    $6,513,667  
    $8,221,552 

    LIABILITIES AND STOCKHOLDERS’
    EQUITY 

    Current liabilities: 

    Accounts payable 
    $987,311  
    $604,789 
  
    Accrued expenses 
     1,398,722  
     1,149,811 
  
    Unearned revenue 
     24,404  
     33,058 
  
    Operating lease liability,
    current portion 
     127,498  
     94,708 
  
    Finance lease liability,